165 related articles for article (PubMed ID: 34143187)
1. Isavuconazole for treatment of refractory coccidioidal meningitis with concomitant cerebrospinal fluid and plasma therapeutic drug monitoring.
Davis MR; Chang S; Gaynor P; McCreary EK; Allyn P
Med Mycol; 2021 Sep; 59(9):939-942. PubMed ID: 34143187
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole in the Treatment of Coccidioidal Meningitis.
Heidari A; Quinlan M; Benjamin DJ; Laurence B; Mu A; Ngai T; Hoffman WJ; Cohen SH; McHardy I; Johnson R; Thompson GR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559134
[TBL] [Abstract][Full Text] [Related]
3. Isavuconazole as Salvage Therapy for Refractory Pediatric Coccidioidal Meningitis.
Naeem F; Laningham F; Kuzmic B; Clerkin P; McCarty J
Pediatr Infect Dis J; 2021 Mar; 40(3):e128-e131. PubMed ID: 33315746
[TBL] [Abstract][Full Text] [Related]
4. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
5. Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.
Lahmer T; Batres Baires G; Heilmaier M; Schmid RM; Sörgel F; Kinzig M; Huber W; Mayr U; Rasch S
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427296
[TBL] [Abstract][Full Text] [Related]
6. Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.
Borman AM; Hughes JM; Oliver D; Fraser M; Sunderland J; Noel AR; Johnson EM
Med Mycol; 2020 Oct; 58(7):996-999. PubMed ID: 32396168
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
8. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of coccidioidal meningitis with voriconazole.
Cortez KJ; Walsh TJ; Bennett JE
Clin Infect Dis; 2003 Jun; 36(12):1619-22. PubMed ID: 12802765
[TBL] [Abstract][Full Text] [Related]
10. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis.
Heidari A; Sharma R; Shakir Q; Shah M; Clement J; Donnelley MA; Reynolds T; Trigg K; Jolliff J; Kuran R; Johnson R; Thompson GR
Clin Infect Dis; 2023 Jun; 76(12):2196-2199. PubMed ID: 36905151
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis.
Tucker RM; Williams PL; Arathoon EG; Levine BE; Hartstein AI; Hanson LH; Stevens DA
Antimicrob Agents Chemother; 1988 Mar; 32(3):369-73. PubMed ID: 2835002
[TBL] [Abstract][Full Text] [Related]
14. Two Phase 1, Open-Label, Mass Balance Studies to Determine the Pharmacokinetics of
Townsend R; Kato K; Hale C; Kowalski D; Lademacher C; Yamazaki T; Akhtar S; Desai A
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):207-216. PubMed ID: 28750160
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients.
Ashkenazi-Hoffnung L; Bilavsky E; Levy I; Grisaru G; Sadot E; Ben-Ami R; Novikov A; Fischer S; Nahum E; Scheuerman O
Pediatr Infect Dis J; 2020 Aug; 39(8):718-724. PubMed ID: 32251256
[TBL] [Abstract][Full Text] [Related]
18. A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
Wilby KJ
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):281-290. PubMed ID: 29101732
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis.
Sorensen KN; Sobel RA; Clemons KV; Pappagianis D; Stevens DA; Williams PL
Antimicrob Agents Chemother; 2000 Jun; 44(6):1512-7. PubMed ID: 10817701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
